FOLDFOLD
US • —
$0.00
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+20.1% YoY
Gross Margin
88.5%
Health Score
5/10
D/E Ratio
1.43
Confidence
LOW
Business Snapshot
Amicus Therapeutics is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases, with a primary revenue-generating product in its treatment for Pompe disease. The company operates in the specialty pharmaceutical market, positioning itself as a niche leader within the rare disease space with a highly differentiated therapy. The company falls into the micro-cap tier based on market cap data availability, though it has a limited financial history in the provided data. A defining characteristic of Amicus is its high gross margin of 88.5%, typical of a biotech with a proprietary, specialized treatment.
Financial Health
Amicus Therapeutics reports a robust gross margin of 88.5%, indicating strong pricing power and a low cost of goods sold for its proprietary therapy. However, the net margin of -4.3% shows the company is not yet profitable on a trailing twelve-month basis, highlighting the significant operating expenses required to support R&D and sales...
Risk Assessment
- EARNINGS QUALITY — An earnings beat rate of 2 out of 4 recent quarters indicates inconsistent performance relative to analyst expectations, which can erode investor confidence in management's guidance.
- DEBT / LIQUIDITY — A debt-to-equity ratio of 1.43x, while manageable, shows the company operates with a notable level of financial leverage that could constrain flexibility in a rising interest rate environment.
- PROFITABILITY — Despite high gross margins of 88.5%, the company maintains a negative net margin of -4.3%, meaning it is not generating profit from its operations and is reliant on external capital.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Amicus Therapeutics reports a robust gross margin of 88.5%, indicating strong pricing power and a low cost of goods sold for its proprietary therapy. However, the net margin of -4.3% shows the company is not yet profitable on a trailing twelve-month basis, highlighting the significant operating expenses required to support R&D and sales. The balance sheet is a mixed picture: a debt-to-equity ratio of 1.43x suggests moderate leverage, while a current ratio of 2.84x provides ample short-term liquidity. Return on equity is a negative -12.0%, underscoring that the company is currently destroying shareholder equity. Notably, free cash flow is unavailable for this analysis. Overall, the company is in a transitional financial state, prioritizing reinvestment over profitability, which limits its capacity for dividends and increases reliance on capital markets for funding.
- EARNINGS QUALITY — An earnings beat rate of 2 out of 4 recent quarters indicates inconsistent performance relative to analyst expectations, which can erode investor confidence in management's guidance. - DEBT / LIQUIDITY — A debt-to-equity ratio of 1.43x, while manageable, shows the company operates with a notable level of financial leverage that could constrain flexibility in a rising interest rate environment. - PROFITABILITY — Despite high gross margins of 88.5%, the company maintains a negative net margin of -4.3%, meaning it is not generating profit from its operations and is reliant on external capital. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives